The ALS Association has partnered with the MDA to fund a Phase II clinical trial of the NeuRx Diaphragm Pacing System (DPS). NeuRx DPS regulates breathing by stimulating the diaphragm. Diaphragm pacing may help people with chronic breathing problems, including those with ALS, regulate their breathing. The Phase II trial will enroll 180 people with ALS, with 120 receiving the NeuRx DPS and 60 receiving the current standard of treatment.
Click here to read more.Share this: